Cutaneous Sarcoidosis Could Soon Get an Effective Therapy
(MedPage Today) -- ORLANDO--Patients with cutaneous sarcoidosis--a condition with no very effective therapy--saw dramatic improvement with the dual-acting TYK2/JAK1 inhibitor brepocitinib (Lisraya) in a small phase II trial.
Patients...